Nose to brain delivery of Efavirenz nanosuspension for effective neuro AIDS therapy: in-vitro, in-vivo and pharmacokinetic assessment
Authors:
Open Access
- 11 November 2021
- Vol. 7 (11) , e08368
Abstract
No abstract availableKeywords
Funding Information
- Mylan
This publication has 33 references indexed in Scilit:
- Efavirenz Dissolution Enhancement I: Co-MicronizationPharmaceutics, 2012
- Nasal Drug Delivery in Humans2011
- Editorial NeuroAIDS reviewAIDS, 2011
- Dissolution enhancement of efavirenz by solid dispersion and PEGylation techniquesInternational Journal of Pharmaceutical Investigation, 2011
- Downscaling Drug Nanosuspension Production: Processing Aspects and Physicochemical CharacterizationAAPS PharmSciTech, 2009
- EfavirenzExpert Opinion on Pharmacotherapy, 2007
- Modulation of human BCRP (ABCG2) activity by anti-HIV drugsJournal of Antimicrobial Chemotherapy, 2006
- `Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients'AIDS, 2001
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Advanced Drug Delivery Reviews, 2001
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 1997